All Posts

Sometimes, something gets missed from our eyes; often, our ignorance delays the diagnosis of something fatal. Idiopathic Pulmonary fibrosis is a chronic, rare, progressive fibrosing interstitial pneumonia. It is a harsh condition that scars the lung tissues for a lifetime and hampers the normal functioning of th...

Osivax raises USD 9 M to boost its universal flu vaccine approach France based biotech startup company Osivax, has secured USD 9 million in Series A financing. A Belgian-based firm Noshaq along with Anaxago, an innovative investment platform led the financing. The proceeds will be used to further advance the cl...

Myelofibrosis (MF) is a rare type of bone marrow cancer resulting in abnormal functioning of blood-forming cells and fibres. MF belongs to a group of disorders known as myeloproliferative disorders. This condition results in the widespread scarring of bone marrow leading to anaemia decreased count of platelets, and...

NICE recommends Pfizer’s Vizimpro for treating NSCLC Not long ago, Pfizer’s Vizimpro (dacomitinib) a tyrosine kinase inhibitor (TKI), was approved as a first-line monotherapy treatment for adult patients living with locally advanced or metastatic non-small lung cancer (NSCLC). As evaluated by the American Cancer...

Cutaneous T-cell lymphoma (CTCL) is a group of lymphoproliferative disorders characterized by localization of neoplastic T lymphocytes to the skin. Cutaneous T-cell lymphoma can cause rash-like skin redness, slightly raised or scaly round patches on the skin, itchy skin, discoloured patches on the skin, enlarged ly...

Generalized pustular psoriasis (GPP) is a severe form of rare skin condition caused by abnormal inflammation.  It is a type of psoriasis, which is characterized by long-lasting abnormal dry-skin patches all over the body. Bodies of the patients suffering from GPP develop red and tender skin covered with pus-fi...

EU approves the use of Libtayo for cutaneous squamous cell carcinoma The National Institute for Health and Care Excellence (NICE), in a move to make cancer drugs available to common man, has issued guidelines regarding the funding of Libtayo (cemiplima). Libtayo, co-developed by Sanofi and Regeneron, was granted...

Chronic Lower Back Pain (CLBP) market size in 7MM is expected to grow at a CAGR of 4.84% for the study period (2017-2028). The CLBP therapy market although, is entirely dependent on supportive therapies, but the drugs such as opioids and NSAIDs, have also been approved to ease the pain associated with CLBP. The pre...

Pfizer’s Zirabev gets FDA nod for the treatment of five types of cancer The US FDA has approved Zirabev (bevacizumab-bvzr), a drug developed by Pfizer, for the treatment of five different types of cancer namely metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous no...

Each year, approximately 3.6 million people in the United States complain of Lower back pain (LBP). Among all types of chronic pain, back pain has often been suggested to be the most frequent type and is considered the second most common neurologic disease and most physician visits can be attributed to it. The lowe...